GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (NAS:VCYT) » Definitions » Net-Net Working Capital

Veracyte (Veracyte) Net-Net Working Capital : $2.25 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Veracyte Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Veracyte's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $2.25.

The industry rank for Veracyte's Net-Net Working Capital or its related term are showing as below:

VCYT's Price-to-Net-Net-Working-Capital is ranked worse than
69.57% of 92 companies
in the Medical Diagnostics & Research industry
Industry Median: 5.575 vs VCYT: 9.24

Veracyte Net-Net Working Capital Historical Data

The historical data trend for Veracyte's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Net-Net Working Capital Chart

Veracyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.85 5.66 1.72 1.91 2.51

Veracyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.97 2.07 2.32 2.51 2.25

Competitive Comparison of Veracyte's Net-Net Working Capital

For the Diagnostics & Research subindustry, Veracyte's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veracyte's Price-to-Net-Net-Working-Capital Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Veracyte's Price-to-Net-Net-Working-Capital falls into.



Veracyte Net-Net Working Capital Calculation

Veracyte's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(216.454+0.75 * 40.378+0.5 * 16.128-70.804
-0-0)/73.2647
=2.51

Veracyte's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(209.188+0.75 * 46.665+0.5 * 18.328-81.424
-0-0)/76.4253
=2.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Veracyte  (NAS:VCYT) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Veracyte Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Veracyte's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Veracyte (Veracyte) Business Description

Traded in Other Exchanges
Address
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.
Executives
Phillip G. Febbo officer: Chief Scientific & Med Officer C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
John Leite officer: Chief Commercial Officer-CLIA 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Evan/ Fa Jones director C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
John L Bishop director
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bonnie H Anderson director, officer: President & CEO 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Giulia C Kennedy officer: Chief Scientific & Med Officer 338 MAIN STREET #26E, SAN FRANCISCO CA 94105
Eliav Barr director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Jens Holstein director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Stapley officer: Chief Executive Officer 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Kevin K Gordon director 155 S LIMERICK RD, LIMERICK PA 19468
Jonathan Wygant officer: VP, Chief Accounting Officer 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Annie Mcguire officer: SVP, General Counsel C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Rebecca Chambers officer: Chief Financial Officer 3052 ORCHARD DR., SAN JOSE CA 95134

Veracyte (Veracyte) Headlines

From GuruFocus